Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (271-280 of 302) with videos related to

Pageof 31
Sort By:
EMBO Molecular Medicine|August 26, 2025
EMT-ciliary signaling in quasi-mesenchymal-stem-like cells drives therapeutic resistance and is a druggable vulnerability in triple-negative breast cancerCamille E Tessier, Jennifer Derrien, Aurore M M Dupuy, et al.
Cell Reports. Medicine|July 9, 2025
A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancerFlorian Dilasser, Lindsay Rose, Agnès Quemener, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Clinical Pharmacology and Therapeutics|August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD TrialEnora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2Gabriel N Hortobagyi, David Chen, Martine Piccart, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2020
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysisElvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
Nature|May 24, 2019
Genomic characterization of metastatic breast cancersFrançois Bertucci, Charlotte K Y Ng, Anne Patsouris, et al.
Pageof 31

Showing results (271-280 of 302) with videos related to

Sort By:
Pageof 31
EMBO Molecular Medicine|August 26, 2025
EMT-ciliary signaling in quasi-mesenchymal-stem-like cells drives therapeutic resistance and is a druggable vulnerability in triple-negative breast cancerCamille E Tessier, Jennifer Derrien, Aurore M M Dupuy, et al.
Cell Reports. Medicine|July 9, 2025
A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancerFlorian Dilasser, Lindsay Rose, Agnès Quemener, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
Clinical Pharmacology and Therapeutics|August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD TrialEnora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2Gabriel N Hortobagyi, David Chen, Martine Piccart, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2020
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysisElvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
Nature|May 24, 2019
Genomic characterization of metastatic breast cancersFrançois Bertucci, Charlotte K Y Ng, Anne Patsouris, et al.
Pageof 31